Skip to main content

Table 1 Patient characteristics

From: Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

 

n. (%)

Total number of patients

100

Age

 

   < 61

55 (55)

   ≥ 61

45 (45)

Clinical Stage

 

   I, II

38 (38)

   III, IV

62 (62)

Performance status

 

   0–1

77 (77)

   2–4

23 (23)

LDH

 

   N≥

52 (52)

   N <

48 (48)

Extranodal lesion

 

   0–1

68 (68)

   2–4

32 (32)

IPI

 

   Low/low-intermediate

58 (58)

   High/high-intermediate

42 (42)

Albumin

 

   < 3.5 g/dl

26 (26)

   ≥3.5 g/dl

74 (74)

Prophylactic G-CSF

 

   yes

62 (62)

   no

38 (38)

  1. N: normal range; IPI: international prognostic index; G-CSF: granulocyte colony-stimulating factor